(Q33920749)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

0 references

0 references

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

D A Jabs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J T Rosenbaum

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

C S Foster

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G N Holland

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G J Jaffe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J S Louie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R B Nussenblatt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E R Stiehm

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Tessler

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S M Whitcup

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Yocum

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

English

0 references

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Ophthalmology

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

492-513

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

Causes and frequency of blindness in patients with intraocular inflammatory disease

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Purpose of quality standards for infectious diseases. Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Prognosticators for visual outcome in sarcoid uveitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Delayed pubertal growth spurt and normal adult height attainment in boys receiving long-term alternate-day prednisone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Nonassociation of Adrenocorticosteroid Therapy and Peptic Ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

The mortality of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Pharmacokinetics of azathioprine after repeated oral and single intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A placebo controlled, crossover study of azathioprine in Reiter's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Immunosuppressive Therapy for Severe Chronic Uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A controlled trial of azathioprine in Behçet's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

The use of methotrexate in childhood rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Low-dose methotrexate therapy for ocular inflammatory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Methotrexate treatment for sarcoid-associated panuveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Rescue therapy with mycophenolate mofetil in refractory uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Immunosuppressive agents: recent developments in molecular action and clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclosporine: the principal immunosuppressant for renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Renal histopathologic alterations in patients treated with cyclosporine for uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A clinical trial of FK506 in refractory uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

FK506 treatment of noninfectious uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Clinical pharmacokinetics of cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Clinical Pharmacokinetics of Cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

7 January 2021

Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Wegener Granulomatosis: An Analysis of 158 Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclophosphamide Therapy of Peripheral Uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Immunosuppressive Therapy in Ocular Cicatricial Pemphigoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Preserving ovarian function in patients receiving cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Treatment of Behçet's disease with chlorambucil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Treatment of Behcet disease with chlorambucil. A follow-up report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Long-lasting remission of Behcet's disease after chlorambucil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Chlorambucil in Behçet's disease. A reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Triple Agent Immunosuppression in Serpiginous Choroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Pars planitis: clinical features and class II HLA associations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

BEHCET'S DISEASE; A REPORT OF 28 CASES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

The ocular manifestations of Behçet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

The rate of visual loss in Behçet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclophosphamide therapy of Behcet's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Birdshot retinochoroidopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Vitiliginous Chorioretinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A New Chorioretinopathy Associated by Anterior Uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Multifocal Choroiditis and Choroidal Neovascularization Associated with the Multiple Evanescent White Dot and Acute Idiopathic Blind Spot Enlargement Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Recurrent multifocal choroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

A follow-up study on serpiginous choroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Macular geographic helicoid choroidopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Cyclosporine-A in the treatment of serpiginous choroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Scleritis and episcleritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Immunosuppressive therapy for progressive ocular cicatricial pemphigoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Treatment of Uveitis by Oral Administration of Retinal Antigens: Results of a Phase I/II Randomized Masked Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

The treatment of refractory uveitis with intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

RETRACTED: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Effects of immunosuppressive drugs during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Changing patterns in uveitis of childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

Behçet's disease. Report of 41 cases and a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

inferred from DOI database lookup

7 January 2021

based on heuristic

HLA typing in birdshot chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900659-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(00)00659-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11024423%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference